{"pageProps":{"initialStudiesData":{"page":{"totalFilteredElements":20},"studies":[{"active":true,"description":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter \nStudy of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell \nLung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent \nChemoradiation Therapy","eudractNumber":"2023-506235-15","id":9281,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"}],"mutations":[],"nctNumber":"NCT06117774","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-12-13T10:24:08+01:00","shortTitle":"AMG 757 20230016 (DeLLphi-306)","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)","eudractNumber":"2024-511838-12-00","id":9817,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"}],"mutations":[],"nctNumber":"NCT06598306","phase":{"id":"ph_14","name":"Phase I/IB"},"recruitmentStart":"2024-11-26T10:56:41+01:00","shortTitle":"AMG 757 20230298 (DeLLphi-308)","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A\nPhase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in\ncombination with Durvalumab, Carboplatin and Etoposide versus Durvalumab,\nCarboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer\n(DeLLphi-312)","eudractNumber":"2024-520050-38","id":10677,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"}],"mutations":[],"nctNumber":"NCT07005128","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-30T12:23:23+02:00","shortTitle":"AMG 757 20240178 (DeLLphi-312)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A\nPhase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig\nor Pembrolizumab Monotherapy for the First-line Treatment of Patients with\nPD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)","eudractNumber":"2024-517780-24-00","id":10715,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06868277","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-30T10:57:06+01:00","shortTitle":"ARTEMIDE-Lung04","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase 2/3 Open Label Randomized Study of\nTelisotuzumab Adizutecan Compared to Standard of Care in Subjects with Locally\nAdvanced or Metastatic EGFR-Mutated Non-Squamous Non- Small Cell Lung Cancer\nAfter Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713","eudractNumber":"2025-521124-29-00","id":11332,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"EGFR","id":"mt_1"}],"nctNumber":"NCT07155187","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2026-03-02T10:56:01+01:00","shortTitle":"Abbvie M25-713 AndroMETa-Lung-713","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"<p class=\"MsoNormal\">A First &#8211; in Human\nPhase I, non-randomized, open-label, multicenter dose escalation trial of BI\n764532 administered by repeated intravenous infusions in patients with Small\nCell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3</p>","eudractNumber":"2019-000729-31","id":6385,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[{"name":"DLL3 (Delta-like 3)","id":"mt_29"}],"nctNumber":"NCT04429087","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2021-10-14T14:19:12+02:00","shortTitle":"BI 1438-0001","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"<p class=\"MsoNormal\">A Phase 1/2 Study of BMS-986340 as Monotherapy and in\nCombination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors&#160;<br /></p><p class=\"MsoNormal\">EUDRA-CT Nummer ge&#228;ndert 18.12.2023<br /></p><p class=\"MsoNormal\">von 2021-001188-26 auf&#160; 2023-503651-10-00<br /></p>","eudractNumber":"2023-503651-10","id":7045,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[],"nctNumber":"NCT04895709 ","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2022-07-14T10:18:54+02:00","shortTitle":"BMS CA052-002","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"<div>A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus</div><div>Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with</div><div>Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung</div><div>Cancer with KRAS G12C Mutation (KRYSTAL-4)</div>","eudractNumber":"2024-515698-85-00","id":11377,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"KRAS","id":"mt_7"},{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS-G12C","id":"mt_250"},{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06875310","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-30T08:29:20+02:00","shortTitle":"BMS CA239-0004 (KRYSTAL-4)","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of \nBMS-986504 Monotherapy in Participants with Advanced or Metastatic Non-small Cell Lung \nCancer (NSCLC) with Homozygous MTAP Deletion After Progression on Prior Therapies","eudractNumber":"2024-519814-29","id":10710,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"ALK","id":"mt_11"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF","id":"mt_9"},{"name":"EGFR","id":"mt_1"},{"name":"HER2/neu","id":"mt_19"},{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS","id":"mt_7"},{"name":"NTRK","id":"mt_81"},{"name":"RET (Rezeptor-Tyrosinkinase)","id":"mt_76"},{"name":"ROS-1 (c-ros oncogene 1, receptor tyrosine kinase)","id":"mt_12"}],"nctNumber":"NCT06855771","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-09-12T13:09:19+02:00","shortTitle":"BMS-CA240-0009","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"Klinische Plattform zur Erforschung molekularer Ver&#228;nderung und der Behandlung von Nicht-Kleinzelligem Lungenkrebs","eudractNumber":null,"id":3383,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[],"nctNumber":"NCT02622581","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2015-08-16T08:23:05+02:00","shortTitle":"CRISP","therapeutical":false,"therapyLines":[]}]},"initialUrl":"/api/studies?ifs=lun&lang=de&page=0&size=10","jsonDlt":"{\"name\":\"Studien des CCC Mainfranken\",\"numberOfItems\":10,\"itemListElement\":[{\"position\":1,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter \\nStudy of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell \\nLung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent \\nChemoradiation Therapy\",\"name\":\"AMG 757 20230016 (DeLLphi-306)\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9281\"}},{\"position\":2,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)\",\"name\":\"AMG 757 20230298 (DeLLphi-308)\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9817\"}},{\"position\":3,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A\\nPhase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in\\ncombination with Durvalumab, Carboplatin and Etoposide versus Durvalumab,\\nCarboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer\\n(DeLLphi-312)\",\"name\":\"AMG 757 20240178 (DeLLphi-312)\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10677\"}},{\"position\":4,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A\\nPhase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig\\nor Pembrolizumab Monotherapy for the First-line Treatment of Patients with\\nPD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)\",\"name\":\"ARTEMIDE-Lung04\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10715\"}},{\"position\":5,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase 2/3 Open Label Randomized Study of\\nTelisotuzumab Adizutecan Compared to Standard of Care in Subjects with Locally\\nAdvanced or Metastatic EGFR-Mutated Non-Squamous Non- Small Cell Lung Cancer\\nAfter Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713\",\"name\":\"Abbvie M25-713 AndroMETa-Lung-713\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11332\"}},{\"position\":6,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"<p class=\\\"MsoNormal\\\">A First &#8211; in Human\\nPhase I, non-randomized, open-label, multicenter dose escalation trial of BI\\n764532 administered by repeated intravenous infusions in patients with Small\\nCell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3</p>\",\"name\":\"BI 1438-0001\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/6385\"}},{\"position\":7,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"<p class=\\\"MsoNormal\\\">A Phase 1/2 Study of BMS-986340 as Monotherapy and in\\nCombination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors&#160;<br /></p><p class=\\\"MsoNormal\\\">EUDRA-CT Nummer ge&#228;ndert 18.12.2023<br /></p><p class=\\\"MsoNormal\\\">von 2021-001188-26 auf&#160; 2023-503651-10-00<br /></p>\",\"name\":\"BMS CA052-002\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/7045\"}},{\"position\":8,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"<div>A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus</div><div>Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with</div><div>Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung</div><div>Cancer with KRAS G12C Mutation (KRYSTAL-4)</div>\",\"name\":\"BMS CA239-0004 (KRYSTAL-4)\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11377\"}},{\"position\":9,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of \\nBMS-986504 Monotherapy in Participants with Advanced or Metastatic Non-small Cell Lung \\nCancer (NSCLC) with Homozygous MTAP Deletion After Progression on Prior Therapies\",\"name\":\"BMS-CA240-0009\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10710\"}},{\"position\":10,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Klinische Plattform zur Erforschung molekularer Ver&#228;nderung und der Behandlung von Nicht-Kleinzelligem Lungenkrebs\",\"name\":\"CRISP\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/3383\"}}],\"url\":\"https://cccmf-studien-homepage.vercel.app/studies?ifs=lun&page=1\"}","__lang":"de","__namespaces":{"common":{"app_title":"Comprehensive Cancer Center Mainfranken Studiendatenbank","app_description":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","app_version":"Version","central_contacts":"Ihre Ansprechpartnerin im CCC MF","email_label":"E-Mail","contact_info_email":"anmeldung_ccc@ukw.de","contact_info_email_title":"E-Mail der Anmeldung des Comprehensive Cancer Center Mainfranken","fax_label":"Fax","contact_info_fax_number":"+49 931 201-35359","contact_info_fax_number_title":"Faxnummer des Comprehensive Cancer Center Mainfranken","phone_label":"Tel.","contact_info_phone_number":"+49 931 201-35350","contact_info_phone_number_title":"Telefonnummer des Comprehensive Cancer Center Mainfranken","website_label":"Webseite","contact_info_website":"https://www.med.uni-wuerzburg.de/ccc/startseite/","contact_info_website_title":"Webseite des Comprehensive Cancer Center Mainfranken","comprehensive_cancer_center_mainfranken_cccmf":"Comprehensice Cancer Centers Mainfranken (CCC MF)","profile_picture_alt_text":"Foto von {{ name }}","close_menu_title":"Studienfilter ausblenden","open_menu_title":"Studienfilter einblenden","search_button_label":"Suchen","text_field_search_label":"Suche...","text_field_clear_buton_title":"Textfeld leeren","hide_filter_button_text":"Filter ausblenden","show_filter_button_text":"Filtern","back_url_title":"Zurück","imprint":"Impressum","data_protection":"Datenschutz","accessibility":"Barrierefreiheit","studies_list_breadcrumb_label":"Studienliste","tree_view_check_boxes_number_of_studies":"{{numberOfStudies}} Treffer, wenn dieser Filter aktiviert wird","footer_logo_ccc_title":"Zur Webseite des CCC Mainfranken","footer_logo_ozw_title":"Zur Webseite des Onkologischen Zentrums Würzburg","footer_logo_ukw_title":"Zur Webseite des Universitätsklinikums Würzburg","footer_logo_isz_ectu_title":"Zur Webseite des Interdisziplinären Studienzentrums mit ECTU","loading":"Laden...","landing_page_name":"Startseite","theme_dark":"Hell","theme_light":"Dunkel","study_status_active":"Rekrutierung läuft","study_status_inactive":"Rekrutierung beendet"},"filters":{"includeinactive":"Nicht rekrutierende Studien auch anzeigen","indications":"Nach Erkrankungen filtern","isonly":"Nur Therapiestudien anzeigen","therapy_lines":"Nach Therapielinien filtern","mutations":"Nach molekularen Markern filtern","organizations":"Nach studienaktiven Standorten filtern","phases":"Nach Phasen filtern","reset_filter":"Filter zurücksetzen","filters_selected_alert_message":"Filter aktiv","reset_all_filters":"Filter zurücksetzen","close_filters_menu":"Zurück zu den Suchergebnissen"},"home":{"banner_alt":"Logo des Comprehensive Cancer Center Mainfranken","logo_alt":"Logo des Comprehensive Cancer Center Mainfranken","subtitle":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","title":"CCC MF Studiendatenbank"},"paginatedList":{"number_of_items_found_text":"Seite {{page}} - Studien {{start}} bis {{end}} von insgesamt {{total}}","no_items_found":"Es wurden keine Einträge gefunden.","pagination_item_aria_label_current_page":"Aktuelle Seite, Seite {{page}}","pagination_item_aria_label_page":"Zu Seite {{page}} navigieren","pagination_item_aria_label_next_page":"Zur nächsten Seite, Seite {{page}} navigieren","pagination_item_aria_label_previous_page":"Zur vorherigen Seite, Seite {{page}} navigieren"},"studiesList":{"alert_text":"Hier finden Sie grundlegende Angaben zu klinischen Studien des ","button_aria_label_details":"Zu den Details der Studie {{shortTitle}}","button_label_details":"Mehr Informationen","indications":"Indikationen","mutations":"Molekulare Marker"}}},"__N_SSP":true}